Out of 2 analysts covering NewLink Genetics (NASDAQ:NLNK), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. NewLink Genetics has been the topic of 2 analyst reports since March 23, 2016 according to StockzIntelligence Inc. SunTrust downgraded the stock on May 11 to “Neutral” rating. Below is a list of NewLink Genetics Corp (NASDAQ:NLNK) latest ratings and price target changes.
11/05/2016 Broker: SunTrust Old Rating: Buy New Rating: Neutral Downgrade
23/03/2016 Broker: Robert W. Baird Rating: Outperform New Target: $27.00 Initiate
About 178,207 shares traded hands. NewLink Genetics Corp (NASDAQ:NLNK) has declined 49.71% since February 8, 2016 and is downtrending. It has underperformed by 66.20% the S&P500.
NewLink Genetics Corporation is a biopharmaceutical firm focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The company has a market cap of $312.68 million. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. It currently has negative earnings. The Company’s biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.
The institutional sentiment decreased to 0.73 in 2016 Q2. Its down 0.18, from 0.91 in 2016Q1. The ratio turned negative, as 34 funds sold all NewLink Genetics Corp shares owned while 32 reduced positions. 11 funds bought stakes while 37 increased positions. They now own 14.35 million shares or 17.92% less from 17.49 million shares in 2016Q1.
Tiverton Asset Management Llc holds 0.77% of its portfolio in NewLink Genetics Corp for 288,807 shares. Knoll Capital Management Lp owns 102,437 shares or 0.37% of their US portfolio. Moreover, Bogle Investment Management L P De has 0.36% invested in the company for 460,146 shares. The California-based Wall Street Associates has invested 0.36% in the stock. Endurant Capital Management Lp, a California-based fund reported 62,491 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.